Eli Lilly partners with China’s InnoCare on drug development deal worth up to $3.35 billion
read at Endpoints ↗DealPositive
Eli Lilly has signed a partnership agreement with Beijing-based InnoCare to co-develop new medicines.
InnoCare will apply its internal drug discovery platform while Lilly will contribute its development and commercialization expertise.
The deal includes potential milestone payments that could total up to $3.35 billion if the joint candidates reach the market.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “In another China pact, Lilly makes a deal with InnoCare worth up to $3.35B”
read at Endpoints ↗86 words · retrieved 52m ago
comments(0)
5-min edit window · permanent after that